CCL4 and rheumatoid arthritis: Similarly, the docking simulations for MIP1b and TRAIL showed promising binding affinities (MIP1b: −6.0 to 7.6 kcal/mol and TRAIL: −7.7 to 8.2 kcal/mol, respectively), and supported their potential therapeutic relevance in RA treatment.